James Y Zhang1, Brent D Weinberg2, Ranliang Hu2, Amit Saindane2, Mark Mullins2, Jason Allen2, Michael J Hoch3. 1. Emory University School of Medicine, Atlanta, Georgia. 2. Department of Radiology and Imaging Sciences, Section of Neuroradiology, Emory University, Atlanta, Georgia. 3. Department of Radiology, Section of Neuroradiology, Pennsylvania University Hospital, 3400 Spruce Street STE 130, Philadelphia, PA 19104. Electronic address: Michael.Hoch@Pennmedicine.upenn.edu.
Abstract
RATIONALE AND OBJECTIVES: Determine the objective benefits of structured reporting of brain tumors through Brain tumor-RADS (BT-RADS) by analyzing discrete quantifiable metrics of the reports themselves. MATERIALS AND METHODS: Following Institutional Review Board approval, post-treatment glioma reports were acquired from two matched 3-month time periods for pre- and postimplementation of BT-RADS. The reports were analyzed for presence of history words, such as "Avastin" and "methylguanine-DNA methyltransferase," as well as hedge words, such as "Possibly" and "Likely." The word counts of the total report and of the impression section were also assessed, as well as whether or not the report contained addenda. RESULTS: In total, 211 pre-BT-RADS and 172 post-BT-RADS reports were analyzed. Post-BT-RADS reports demonstrated greater reporting of history words, including "Avastin" (7.6% vs. 20.9%, p < 0.001) and "methylguanine-DNA methyltransferase" (10.9% vs. 31.4%, p < 0.0001). They also demonstrated reduced usage of hedge words, including "Possibly" (3.8% vs. 0.6%, p < 0.05) and "Likely" (49.8% vs. 28.5%, p < 0.01). Furthermore, post-BT-RADS reports possessed fewer words in total report length (389 vs. 245.2, p < 0.001), as well as in the impression section (53.7 vs. 42.6, p < 0.01). Finally, fewer post-BT-RADS reports contained addenda (10% vs. 1.2%, p < 0.01). CONCLUSION: Following implementation of BT-RADS, glioma reports demonstrated greater consistency and completeness of clinical history, less ambiguity, and more conciseness.
RATIONALE AND OBJECTIVES: Determine the objective benefits of structured reporting of brain tumors through Brain tumor-RADS (BT-RADS) by analyzing discrete quantifiable metrics of the reports themselves. MATERIALS AND METHODS: Following Institutional Review Board approval, post-treatment glioma reports were acquired from two matched 3-month time periods for pre- and postimplementation of BT-RADS. The reports were analyzed for presence of history words, such as "Avastin" and "methylguanine-DNA methyltransferase," as well as hedge words, such as "Possibly" and "Likely." The word counts of the total report and of the impression section were also assessed, as well as whether or not the report contained addenda. RESULTS: In total, 211 pre-BT-RADS and 172 post-BT-RADS reports were analyzed. Post-BT-RADS reports demonstrated greater reporting of history words, including "Avastin" (7.6% vs. 20.9%, p < 0.001) and "methylguanine-DNA methyltransferase" (10.9% vs. 31.4%, p < 0.0001). They also demonstrated reduced usage of hedge words, including "Possibly" (3.8% vs. 0.6%, p < 0.05) and "Likely" (49.8% vs. 28.5%, p < 0.01). Furthermore, post-BT-RADS reports possessed fewer words in total report length (389 vs. 245.2, p < 0.001), as well as in the impression section (53.7 vs. 42.6, p < 0.01). Finally, fewer post-BT-RADS reports contained addenda (10% vs. 1.2%, p < 0.01). CONCLUSION: Following implementation of BT-RADS, glioma reports demonstrated greater consistency and completeness of clinical history, less ambiguity, and more conciseness.
Authors: Yasasvi Tadavarthi; Valeria Makeeva; William Wagstaff; Henry Zhan; Anna Podlasek; Neil Bhatia; Marta Heilbrun; Elizabeth Krupinski; Nabile Safdar; Imon Banerjee; Judy Gichoya; Hari Trivedi Journal: Radiol Artif Intell Date: 2022-02-02
Authors: Karthik Ramesh; Saumya S Gurbani; Eric A Mellon; Vicki Huang; Mohammed Goryawala; Peter B Barker; Lawrence Kleinberg; Hui-Kuo G Shu; Hyunsuk Shim; Brent D Weinberg Journal: Tomography Date: 2020-06